Skip to navigation menu Skip to content
Illustration of a calendarIllustration of a document pageIllustration of a heart over a handIllustration of an envelopeIllustration of the letter i inside a circleIllustration of a map markerIllustration of a caduceusIllustration of a user with a plus signIllustration of a telephoneIllustration of a question mark inside a circleIllustration of a video cameraDocument with a PDF label
Current Research Studies

RS_GS_US_320_1092

GS_US_320_1092

What is the goal of the study?

Randomized (2:1), double-blind, placebo-controlled, two-part, multicenter (Approximately 40 centers in North America, Europe, and Asia), study of the pharmacokinetics, safety, tolerability, and antiviral activity of the TAF 25 mg tablet administered once daily for 24 weeks in treatment-naïve and treatment-experienced adolescent subjects with CHB. A total of 75 adolescents (12 to < 18 years of age) will be enrolled to receive the TAF 25 mg tablet or matching placebo once daily.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: